Comprehensive historical analysis of global market for Polycythemia Vera has thoroughly analyzed in this report. It offers data and insights from 2019-2022, and provides extensive market forecasts from 2023-2032 by region/country and subsectors. It covers the price, sales volume, revenue, historical growth, gross margin, and future outlooks for the Polycythemia Vera market.

The Global Polycythemia Vera Market size is expected to grow from USD 1.35 billion in 2025 to USD 2.34 billion by 2035, at a CAGR of 5.65% during the forecast period 2025-2035.

The report includes growth prospects in the global Polycythemia Vera market by type, application, sub segement and region and QMI has compiled a comprehensive detailed research report to offer insights. The report details consumption in the Healthcare and other sectors. Regional coverage spans North America, Europe, and rest of the world including Asia Pacific.

Leading players of Polycythemia Vera including:

1. Incyte Corporation
2. Novartis AG
3. PharmaEssentia Corporation
4. Bristol Myers Squibb Company
5. Protagonist Therapeutics
6. Disc Medicine
7. Italfarmaco S.p.A.
8. AOP Orphan Pharmaceuticals
9. Ionis Pharmaceuticals
10. Silence Therapeutics
11. Merck & Co., Inc.
12. F. Hoffmann-La Roche Ltd.

 Request To Download Free Sample copy of the report @ https://www.sphericalinsights.com/request-sample/4704

Market split by Segement, can be divided into:

 By Indication

• Primary Polycythemia Vera
• Secondary Polycythemia Vera

 By Treatment Type

• Phlebotomy
• Cytoreductive Medications
• Supportive Care
• Other

Market segment by Region/Country including:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

Check discount for this report: https://www.sphericalinsights.com/request-discount/4704

In March 2026, Takeda submitted the New Drug Application (NDA) for rusfertide to the FDA, marking a major regulatory milestone for potential market approval. This submission underscores the progress toward making a novel therapy available to PV patients and reflects the growing investment in expanding treatment options within the market.

In December 2025, 52?week extended VERIFY trial data confirmed sustained hematocrit control for rusfertide, supporting durable clinical response over long-term use. These results strengthened confidence among physicians and stakeholders regarding the therapy’s safety, efficacy, and commercial prospects in the PV market.

In August 2025, the FDA granted Breakthrough Therapy Designation to rusfertide, accelerating regulatory review for its use in treating erythrocytosis associated with PV. This designation recognized the therapy’s potential clinical benefit and positioned rusfertide to significantly influence treatment protocols and market adoption.

In June 2025, Takeda presented Phase?3 VERIFY clinical trial results for rusfertide, showing improved hematocrit control and reduced reliance on phlebotomy in PV patients. This pivotal study reinforced rusfertide’s potential as a disease-modifying therapy and demonstrated its capacity to address unmet clinical needs in Polycythemia Vera management.

In February 2025, a major polycythemia vera market insight and forecast report was published, highlighting JAKAFI (ruxolitinib) and BESREMi as leading therapies. The report emphasized emerging treatments and diagnostic advances, providing a comprehensive outlook on market trends, future growth drivers, and competitive dynamics shaping the global PV landscape.

Access full Report with Table of Content @ https://www.decisionsadvisors.com/reports/polycythemia-vera-market

Whats covered in the report?

• 1. Overview of the Polycythemia Vera market.
• 2. The current and forecasted regional (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa) market size data for the Polycythemia Vera market, based on segement.
• 3. Polycythemia Vera Market trends.
• 4. Polycythemia Vera Market drivers.
• 5. Analysis of major company profiles.

Reasons to buy this Market Report:

1. Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Polycythemia Vera market.

2. Use the SWOT analysis to determine the competitive intensity and therefore attractiveness of the emerging Polycythemia Vera Industry.

3. Leading company profiles reveal details of key Polycythemia Vera market players emerging five operations and financial performance.

4. Add weight to presentations and pitches by understanding the future growth prospects of the emerging Polycythemia Vera market with five year historical forecasts.

5. Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region.

6. Extensive information on factors that will amplify the growth of the Polycythemia Vera market over the upcoming seven years

7. Accurate estimation of the global Polycythemia Vera market size

8. Exact estimations of the upcoming trends and changes observed in the consumer behavior

9. Growth of the global Polycythemia Vera market across the North & South America, EMEA, Asia Pacific, and Latin America

10. Information about Polycythemia Vera market growth potential

11. In-depth analysis of the industry’s competitive landscape and detailed information vis-a-vis on various vendors

12. Furnishing of detailed information on the factors that will restrain the growth of the Polycythemia Vera market

About the Spherical Insights

Spherical Insights is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.

Contact Us:

Company Name: Spherical Insights

Email: sales@sphericalinsights.com

Phone: +1 303 800 4326 (US)

Follow Us: LinkedIn | Facebook | Twitter